Global Medical REIT Inc. (GMRE) Analysts See $0.17 EPS on May, 10

May 3, 2018 - By Joshua Cleveland

Global Medical REIT Inc. (NYSE:GMRE) Corporate Logo

Global Medical REIT Inc. (NYSE:GMRE)’s quarterly earnings will be reported on May, 10., according to Faxor. The EPS diference is $0.15 or 750.00 % up from last years number. Previous year: $0.02; Analysts forcast: $0.17. If the current EPS of $0.17 is accurate, GMRE’s profit could hit $3.75 million. 13.33 % EPS growth is what analysts predict. $0.15 EPS was reported for last quarter. Ticker’s shares touched $8.16 during the last trading session after 2.64% change.Global Medical REIT Inc. has volume of 94,592 shares. Since May 3, 2017 GMRE has declined 20.98% and is downtrending. GMRE underperformed by 32.53% the S&P500.

Global Medical REIT Inc. (NYSE:GMRE) Ratings Coverage

Total analysts of 2 have positions in Global Medical REIT (NYSE:GMRE) as follows: 2 rated it a “Buy”, 0 with “Sell” and 0 with “Hold”. The positive are 100%. Since November 10, 2017 according to StockzIntelligence Inc Global Medical REIT has 2 analyst reports. On Monday, November 13 the rating was maintained by Cantor Fitzgerald with “Buy”.

Global Medical REIT Inc. is a Maryland corporation engaged primarily in the acquisition of licensed, state-of-the-art, purpose-built healthcare facilities and the leasing of these facilities to strong clinical operators with leading market share.The firm is worth $179.79 million. The Company's strategy is to produce increasing, reliable rental revenue by expanding its portfolio, and leasing its healthcare facilities to market-leading operators under long-term triple-net leases.Last it reported negative earnings. The Company's management team has significant healthcare, real estate and public real estate investment trust, or REIT, experience and has long-established relationships with a wide range of healthcare providers.

Global Medical REIT Inc. (NYSE:GMRE) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: